Literature DB >> 23159314

Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.

P Thakur1, B Nehru.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder manifesting in motor, cognitive and behavioral anomalies. Loss of dopaminergic neurons in the substantia nigra region of the brain is the hallmark feature of PD, which is attributed to oxidative and inflammatory stress besides other diverse factors and hence drugs targeting these pathways hold promise as neuro-therapeutics. The anti-oxidative as well as anti-inflammatory properties of sodium salicylate (SS), suggest its neuroprotective potentials in PD. Since PD is a progressive neurodegenerative disorder, the mechanistic basis for utilizing SS as a neuroprotectant in PD could be better understood in the chronic models. The present study utilizes a rotenone-based model of PD to evaluate the neuro-modulatory efficacy of SS. Subcutaneous injection of rotenone (2mg/kg body weight) was given to male SD rats every day, for a period of 5 weeks, which developed all the essential features of PD in these animals. Simultaneously, another group was injected SS intraperitoneally at the dose of 100mg/kg body weight, in addition to the rotenone. In the animals receiving rotenone+SS, significant improvement was observed in the various characteristic hallmarks of PD such as dopamine and tyrosine hydroxylase levels as well as the motor dysfunction symptoms. It attenuated the reactive oxygen species levels significantly but failed to reduce the levels of protein carbonylation and lipid peroxidation. However, SS effectively abridged the levels of inflammatory mediators like cyclooxygenase-2 (COX-2), nuclear factor kappa B and inducible nitric oxide synthase. Correspondingly, a significant decrease in the levels of pro-inflammatory cytokines interleukin-6, interleukin-1β and tumor necrosis factor-α was also observed following SS co-treatment. Thus, neuroprotective efficacy of SS in this chronic model of PD can be largely attributed to its anti-inflammatory effects rather than its free radical-scavenging properties.
Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159314     DOI: 10.1016/j.neuroscience.2012.11.006

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  21 in total

Review 1.  A Review on Potential Footprints of Ferulic Acid for Treatment of Neurological Disorders.

Authors:  Surabhi Thapliyal; Tanveer Singh; Shailendra Handu; Manisha Bisht; Puja Kumari; Priyanka Arya; Pallavi Srivastava; Ravi Gandham
Journal:  Neurochem Res       Date:  2021-02-05       Impact factor: 3.996

2.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

3.  Neuroprotective Effects of Filgrastim in Rotenone-Induced Parkinson's Disease in Rats: Insights into its Anti-Inflammatory, Neurotrophic, and Antiapoptotic Effects.

Authors:  Mariama S Azmy; Esther T Menze; Reem N El-Naga; Mariane G Tadros
Journal:  Mol Neurobiol       Date:  2018-01-11       Impact factor: 5.590

4.  Protective Effect of Spermidine Against Excitotoxic Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and Neuroinflammatory Mechanism.

Authors:  Sumit Jamwal; Shamsher Singh; Navneet Kaur; Puneet Kumar
Journal:  Neurotox Res       Date:  2015-06-16       Impact factor: 3.911

Review 5.  M1 and M2 immune activation in Parkinson's Disease: Foe and ally?

Authors:  M S Moehle; A B West
Journal:  Neuroscience       Date:  2014-11-25       Impact factor: 3.590

6.  Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.

Authors:  Jang-Won Lee; Victor Tapias; Roberto Di Maio; J Timothy Greenamyre; Jason R Cannon
Journal:  Neurobiol Aging       Date:  2014-07-15       Impact factor: 4.673

7.  Antidepressant and antioxidative effect of Ibuprofen in the rotenone model of Parkinson's disease.

Authors:  Tiago Zaminelli; Raísa Wendhausen Gradowski; Taysa Bervian Bassani; Janaína Kohl Barbiero; Ronise M Santiago; Daniele Maria-Ferreira; Cristiane Hatsuko Baggio; Maria A B F Vital
Journal:  Neurotox Res       Date:  2014-04-17       Impact factor: 3.911

8.  Inhibition of neuroinflammation and mitochondrial dysfunctions by carbenoxolone in the rotenone model of Parkinson's disease.

Authors:  Poonam Thakur; Bimla Nehru
Journal:  Mol Neurobiol       Date:  2014-06-20       Impact factor: 5.590

9.  Tetramethylpyrazine Ameliorates Rotenone-Induced Parkinson's Disease in Rats: Involvement of Its Anti-Inflammatory and Anti-Apoptotic Actions.

Authors:  Haidy E Michel; Mariane G Tadros; Ahmed Esmat; Amani E Khalifa; Ahmed M Abdel-Tawab
Journal:  Mol Neurobiol       Date:  2016-08-11       Impact factor: 5.590

10.  β-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease.

Authors:  Shreesh Ojha; Hayate Javed; Sheikh Azimullah; M Emdadul Haque
Journal:  Mol Cell Biochem       Date:  2016-06-17       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.